ABBV Stock Price, Chart, Stats & News
ABBV chart
Fundamentals
Gross margin | 73.34% |
Operating margin | 26.72% |
Pretax margin | 10.79% |
Net margin | 6.91% |
Effective tax rate | 35.83% |
ROA | 3.15% |
ROE | -361.58% |
D/E | -21.06x |
Interest coverage ratio | 5.77x |
ABBV valuation
P/E | 114.74x |
P/S | 6.05x |
P/B | -113.99x |
P/CF | 19.59x |
P/FCF | 19.80x |
P/OCF | 19.59x |
PEG | 1.13x |
EV multiple | 10.83x |
About
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Similar securities
Based on sector and market capitalization
